BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 33667951)

  • 1. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer.
    Khan A; Sarkar E
    Cancer Treat Res Commun; 2022; 33():100641. PubMed ID: 36193597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
    Liu X; Zhao Y
    Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene editing and CRISPR in the clinic: current and future perspectives.
    Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
    Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
    Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
    Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.
    Khalaf K; Janowicz K; Dyszkiewicz-Konwińska M; Hutchings G; Dompe C; Moncrieff L; Jankowski M; Machnik M; Oleksiewicz U; Kocherova I; Petitte J; Mozdziak P; Shibli JA; Iżycki D; Józkowiak M; Piotrowska-Kempisty H; Skowroński MT; Antosik P; Kempisty B
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32796761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
    Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
    Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment.
    Yang X; Zhang B
    Funct Integr Genomics; 2023 May; 23(2):182. PubMed ID: 37231285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
    Lu Y; Xue J; Deng T; Zhou X; Yu K; Deng L; Huang M; Yi X; Liang M; Wang Y; Shen H; Tong R; Wang W; Li L; Song J; Li J; Su X; Ding Z; Gong Y; Zhu J; Wang Y; Zou B; Zhang Y; Li Y; Zhou L; Liu Y; Yu M; Wang Y; Zhang X; Yin L; Xia X; Zeng Y; Zhou Q; Ying B; Chen C; Wei Y; Li W; Mok T
    Nat Med; 2020 May; 26(5):732-740. PubMed ID: 32341578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
    Wellhausen N; Agarwal S; Rommel PC; Gill SI; June CH
    Curr Opin Immunol; 2022 Feb; 74():76-84. PubMed ID: 34798542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.